Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Recordati Industria Chimica e Farmaceutica SPA (GB:0KBS)
LSE:0KBS
RESEARCH TOOLSreports
Recordati Industria Chimica e Farmaceutica SPA (0KBS) Share Price & Analysis
0 Followers
0KBS Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€38.99 - €53.40
Previous Close€52.75
Volume40.72K
Average Volume (3M)14.78K
Market Cap
€10.85B
Enterprise Value€12.29B
Total Cash (Recent Filing)€284.73M
Total Debt (Recent Filing)€1.72B
Price to Earnings (P/E)27.9
Beta0.70
Next Earnings
May 09, 2024EPS Estimate
€0.69Next Dividend Ex-DateN/A
Dividend Yield2.22%
Share Statistics
EPS (TTM)1.89
Shares OutstandingN/A
10 Day Avg. Volume24,254
30 Day Avg. Volume14,778
Standard Deviation0.06
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€50.63Price Target Upside3.08% Upside
Rating ConsensusHold
Number of Analyst Covering4
Recordati Industria Chimica e Farmaceutica SPA News
Options Prices
Currently, No data available
---
Ownership Overview
0.08% Insiders
22.78% Mutual Funds
4.94% Other Institutional Investors
72.20% Public Companies and
Individual Investors
0KBS FAQ
What was Recordati Industria Chimica e Farmaceutica SPA’s price range in the past 12 months?
Recordati Industria Chimica e Farmaceutica SPA lowest share price was €38.99 and its highest was €53.40 in the past 12 months.
What is Recordati Industria Chimica e Farmaceutica SPA’s market cap?
Currently, no data Available
When is Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date?
Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date is May 09, 2024 which is in 12 days.
How were Recordati Industria Chimica e Farmaceutica SPA’s earnings last quarter?
Recordati Industria Chimica e Farmaceutica SPA released its earnings results on Feb 22, 2024. The company reported €0.411 earnings per share for the quarter, missing the consensus estimate of €0.515 by -€0.104.
Is Recordati Industria Chimica e Farmaceutica SPA overvalued?
According to Wall Street analysts Recordati Industria Chimica e Farmaceutica SPA’s price is currently Undervalued.
Does Recordati Industria Chimica e Farmaceutica SPA pay dividends?
Recordati Industria Chimica e Farmaceutica SPA does not currently pay dividends.
What is Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate?
Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate is €0.69.
How many shares outstanding does Recordati Industria Chimica e Farmaceutica SPA have?
Recordati Industria Chimica e Farmaceutica SPA has 209,125,150 shares outstanding.
What happened to Recordati Industria Chimica e Farmaceutica SPA’s price movement after its last earnings report?
Recordati Industria Chimica e Farmaceutica SPA reported an EPS of €0.411 in its last earnings report, missing expectations of €0.515. Following the earnings report the stock price went down -0.019%.
Which hedge fund is a major shareholder of Recordati Industria Chimica e Farmaceutica SPA?
Currently, no hedge funds are holding shares in GB:0KBS
---
Recordati Industria Chimica e Farmaceutica SPA Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€50.63 (3.08% Upside)
€50.63 (3.08% Upside)
Insider Transactions
Sold Shares
Worth €6.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.96%
12-Months-Change
Fundamentals
Return on Equity
24.08%
Trailing 12-Months
Asset Growth
5.23%
Trailing 12-Months
Company Description
Recordati Industria Chimica e Farmaceutica SPA
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth strategy. The vast majority of the company's revenue is generated in Italy, followed by France and Germany. Recordati reports two operating segments: specialty and primary care and rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.
---
0KBS Stock 12 Months Forecast
Average Price Target
€50.63
▲(3.08% Upside)
Technical Analysis
Best Analysts Covering 0KBS
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-14.98%
reiterated a sell rating 2 months ago
Copying Charles Pitman CFA's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -14.98% per trade.
---